Biblio Discovery — Demo Discovery Service

664 hasil

Menampilkan 1–20 · 0,31 detik · RSS

Jurnal

EJC Skin Cancer

Scopus

ISSN 2772-6118 · Elsevier · 664 artikel di indeks

  1. Artikel Jurnal

    From immune activation to pathological response: neoadjuvant immunotherapy in cutaneous squamous cell carcinoma. A systematic review and meta-analysis

    Riccardo Gili; Monica Variolo; Fausto Petrelli dkk.

    EJC Skin Cancer, Vol. 4 · 2026 · Inggris · DOAJ Scopus

    Background: Cutaneous squamous cell carcinoma (cSCC) frequently arises in the head and neck region and is associated with significant morbidity when managed with extensive surgery and postoperative radiotherapy. Neoadjuvant immune checkpoint inhibitors (ICI) have emerged as a promising strategy to…

  2. Artikel Jurnal

    Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced cutaneous squamous cell carcinoma

    Jeremy Mo; Ann-Sophie Bohne; Mirjam Nägeli dkk.

    EJC Skin Cancer, Vol. 4 · 2026 · Inggris · DOAJ Scopus

    Aim: Anti-programmed death-1/ligand-1 (anti-PD-(L)1) therapies are effective for advanced cSCC. This international study examines response patterns and subsequent management strategies following anti-PD-(L)1 therapy. Method: This retrospective cohort study involved 10 centres across 6 countries…

  3. Artikel Jurnal

    Complete response with combined sonidegib and pembrolizumab in synchronous advanced basal cell carcinoma and metastatic cutaneous squamous cell carcinoma: A case report

    Paola Valeria Marchese; Carolina Ortiz; Julia Lostes Bardaji dkk.

    EJC Skin Cancer, Vol. 4 · 2026 · Inggris · DOAJ Scopus

    Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most common skin cancers. While most cases are managed with local therapies, advanced disease may require systemic treatment. Hedgehog pathway inhibitors are standard for advanced BCC, whereas PD-1 inhibitors are…

  4. Artikel Jurnal

    Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment

    Carl Maximilian Thielmann; Luisa Richter; Henry Karl Tapken dkk.

    EJC Skin Cancer, Vol. 4 · 2026 · Inggris · DOAJ Scopus

    Background: KIT alterations occur in distinct melanoma subtypes, yet KIT-mutant melanoma remains clinically and biologically heterogeneous and lacks approved KIT-targeted therapy. We characterized clinico-genomic features of KIT-altered melanoma and described outcomes of patients treated with…

  5. Artikel Jurnal

    Neutropenia induced by dabrafenib and trametinib combination therapy in patients with melanoma: Incidence, risk factors and clinical implications

    Jessica Fareau; Nausicaa Malissen; Sandrine Monestier dkk.

    EJC Skin Cancer, Vol. 4 · 2026 · Inggris · DOAJ Scopus

    Neutropenia is a recognized but undercharacterized toxicity of dabrafenib/trametinib (D + T) combination therapy in melanoma. We conducted a retrospective single-center analysis of 171 patients treated with D + T between 2015 and 2020. Any-grade neutropenia occurred in 44 patients, predominantly…